Vildagliptin improves glycemic control in type 2 diabetes patients undergoing hemodialysis

DOI Web Site 43 References
  • Ishioka Kunihiro
    Department of Nephrology, Immunology, and Vascular Medicine, Shonan Kamakura General Hospital
  • Furuya Rei
    Department of Nephrology, Immunology, and Vascular Medicine, Shonan Kamakura General Hospital
  • Iwagami Masao
    Department of Nephrology, Immunology, and Vascular Medicine, Shonan Kamakura General Hospital
  • Tsutsumi Daimu
    Department of Nephrology, Immunology, and Vascular Medicine, Shonan Kamakura General Hospital
  • Mochida Yasuhiro
    Department of Nephrology, Immunology, and Vascular Medicine, Shonan Kamakura General Hospital
  • Oka Machiko
    Department of Nephrology, Immunology, and Vascular Medicine, Shonan Kamakura General Hospital
  • Maesato Kyoko
    Department of Nephrology, Immunology, and Vascular Medicine, Shonan Kamakura General Hospital
  • Moriya Hidekazu
    Department of Nephrology, Immunology, and Vascular Medicine, Shonan Kamakura General Hospital
  • Ohtake Takayasu
    Department of Nephrology, Immunology, and Vascular Medicine, Shonan Kamakura General Hospital
  • Hidaka Sumi
    Department of Nephrology, Immunology, and Vascular Medicine, Shonan Kamakura General Hospital
  • Kobayashi Shuzo
    Department of Nephrology, Immunology, and Vascular Medicine, Shonan Kamakura General Hospital

Bibliographic Information

Other Title
  • 2型糖尿病合併血液透析患者におけるビルダグリプチン投与による血糖改善効果
  • 2ガタ トウニョウビョウ ガッペイ ケツエキ トウセキ カンジャ ニ オケル ビルダグリプチン トウヨ ニ ヨル ケットウ カイゼン コウカ

Search this article

Abstract

[Background and objectives] Since the dipeptidyl peptidase-4 (DPP-4) inhibitor, a therapeutic agent for diabetes mellitus involving incretin, emerged, it has brought about a paradigm shift in the treatment of diabetes mellitus. Among DPP-4 inhibitors, vildagliptin is available not only for patients with renal insufficiency, but also for hemodialysis patients. The purpose of this study was to assess the efficacy and safety of vildagliptin (50 mg once daily), and observe the effect on glucose fluctuations using continuous glucose monitoring (CGM) in hemodialysis patients with type 2 diabetes mellitus (T2DM). [Design, setting, participants, & measurements] The study included 42 hemodialysis patients (26 men: mean age±SD, 68.0±11.2 years) with T2DM who had inadequate glycemic control. We divided them into two groups. Fifty mg/day of vildagliptin was administered to one group (V group) in addition to the original treatment. The other group (C group) continued the original treatment. We assessed HbA1c, glycated albumin (GA), and blood glucose values in the two groups before and 1 month after the treatment. Additionally, we evaluated the averaged glucose value (AGV) and blood glucose fluctuation (SD) for 24 hours using continuous glucose monitoring (CGM). [Results] In the V group, HbA1c and the blood glucose value decreased significantly 1 month after the administration of vildagliptin (6.5±1.1 to 5.6±1.1% and 184±79 to 135±50 mg/dL, p<0.05, respectively). GA also showed improvement in the V group (25.1±5.3 to 22.9±4.4%, p=0.16). CGM showed that AGV and SD improved both one day and one month after vildagliptin administration. [Conclusion] Our data showed that vildagliptin improved blood glucose control rapidly as well as glycemic fluctuations without any adverse effects.

Journal

References(43)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top